Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Flexi Cap Fund median (46 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 07 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Quant Flexi Cap Fund |
|---|---|
| 07 Jan 2013 | ₹100.00 |
| 25 Feb 2014 | ₹82.58 |
| 16 Apr 2015 | ₹150.58 |
| 03 Jun 2016 | ₹151.04 |
| 23 Jul 2017 | ₹225.68 |
| 10 Sep 2018 | ₹227.35 |
| 30 Oct 2019 | ₹222.78 |
| 17 Dec 2020 | ₹315.98 |
| 04 Feb 2022 | ₹532.97 |
| 26 Mar 2023 | ₹521.69 |
| 13 May 2024 | ₹880.61 |
| 02 Jul 2025 | ₹923.91 |
| 20 Aug 2026 | ₹1031.67 |
| Metric | quant · Direct NAV ₹122.94 Very High risk ★★★☆☆ | Category median Flexi Cap Fund · 46 funds |
|---|---|---|
| +15.56% | +4.32% | |
| +17.59% | +14.11% | |
| +16.90% | +12.53% | |
| +19.62% | +13.78% | |
| +18.70% | +14.48% | |
| +16.00% | — | |
| +21.74% | +16.56% | |
| +21.43% | +15.80% | |
| +21.26% | +15.46% | |
| Risk | ||
| 16.78% | 14.19% | |
| 0.66 | 0.53 | |
| 0.91 | 0.73 | |
| -41.28% | -30.01% | |
| Nifty 500 | — | |
| +4.95% | +2.15% | |
| 1.15 | 0.97 | |
| 127.0% | 102.4% | |
| 110.9% | 90.2% | |
| 1.05% | 0.96% | |
| ₹6,713Cr | ₹4,325Cr | |
| 1.00% | — | |
| None | — | |
| ₹250 | — | |
| ₹5.00K | — | |
| 0% | 34% | |
| Sanjeev Sharma | — | |
| 07 Jan 2013 | — | |
| 27 | — | |
| 60.1% | — | |
| 1.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.